Controversies in COX-2 selective inhibition.
Simon
Lee S
LS
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. lsimon@caregroup.harvard.edu
Smolen
Josef S
JS
Abramson
Steven B
SB
Appel
Gerald
G
Bombardier
Claire
C
Brater
D Craig
DC
Breedveld
Ferdinand C
FC
Brune
K
K
Burmester
Gerd R
GR
Crofford
Leslie J
LJ
Dougados
Maxime
M
DuBois
Raymond N
RN
Fitzgerald
Garret A
GA
Frishman
W
W
García Rodríguez
Luis A
LA
Hochberg
Marc C
MC
Kalden
Joachim R
JR
Laine
Loren
L
Langman
Michael J S
MJ
Prescott
Stephen M
SM
van de Putte
Leo B A
LB
Whelton
Andrew
A
White
William B
WB
Willaims
Gordon H
GH
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D001241:Aspirin / Q000009:adverse effects* / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012680:Sensitivity and Specificity
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D001241:Aspirin